Mixed signals in heart failure: Cancer rules

Journal of Clinical Investigation

Volumn 109, Issue 7, 2002, Pages 849-855

  Hoshijima, Masahiko ^a   Chien, Kenneth R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTIFICIAL HEART; CANCER; CELL DEATH; CELL GROWTH; CELL SURVIVAL; DISEASE COURSE; GENE ISOLATION; GENE THERAPY; HEART DILATATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MECHANICAL STRESS; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036213057     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215380     Document Type: Review

References (50)

1. Molecular and cellulat biology of cardiac hypertrophy and failure
2. Oncogenic kinase signalling
3. Genomic circuits and the integrative biology of cardiac diseases
4. Stress pathways and heart failure
5. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways
6. Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load
7. Cytoplasmic signaling pathways that regulate cardiac hypertrophy
8. A novel role for STAT3 in cardiac remodeling
9. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo
10. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles
11. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo
12. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
13. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
14. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy
15. Decoding calcium signals involved in cardiac growth and function
16. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy
17. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo
18. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes
19. Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein
20. GATA-dependent recruitment of MEF2 proteins to target promoters
21. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo
22. Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation
23. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease
24. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor
25. Specific interaction of the potassium channel beta-subunit minK with the sarcomeric protein T-cap suggests a T-tubulemyofibril linking system
26. Electrophysiological remodeling in hypertrophy and heart failure
27. Abnormalities of calcium cycling in the hypertrophied and failing heart
28. Cardiac excitation-contraction coupling
29. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation
30. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: A major contributor to reduced SERCA2 activity
31. Seven-transmembrane-spanning receptors and heart function
32. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy
33. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts
34. Molecular and cellular mechanisms of cardiac arthythmias
35. Cardiac channelopathies
36. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43
37. A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages
38. Congenital heart disease caused by mutations in the transcription factor NKX2-5
39. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome
40. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis
41. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy
42. A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia
43. Regulation of KChIP2 potassium channel beta subunit gene expression underlies the gradient of transient outward current in canine and human ventricle
44. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel
45. Evidence that human cardiac myocytes divide after myocardial infarction
46. Prospects for gene therapy for heart failure
47. Cardiac gene delivery with cardiopulmonary bypass
48. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer
49. Genetics of heart development